13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q4 2022. See the latest, Q2 2026 →
Reported value
$1.72B
−12% on the quarter before
Positions
51
2 new · 0 sold out
Top 10
74.8%
of the value
Est. gain
−$475.4M
on stocks held all quarter
Est. return
−25.7%
on those stocks since Q3 2022
Positions as of Dec 31, 2022, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2022. Striped tiles are options.
Largest buys
Since Q3 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Prime Medicine, Inc.~$246.8MNew · 0.0% → 14.3%+13,284,688 shares
- CrowdStrike~$65.5MNew · 0.0% → 3.8%+622,073 shares
- Gitlab Inc.~$31.9MAdded · 1.6% → 3.4%+701,123 shares
- Eqrx Inc.~$302,061Added · 12.0% → 6.8%+122,789 shares
Largest sells
Since Q3 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$84.9MCut · 8.2% → 8.2%−750,000 shares
- Lyft Inc~$9.7MCut · 4.1% → 3.4%−880,591 shares
- Verve Therapeutics Inc.~$8.2MCut · 19.2% → 11.9%−424,925 shares
- Velo3d Inc~$7.7MCut · 1.0% → 0.1%−4,327,600 shares
- Rani Therapeutics Hldgs Inc.~$1.2MCut · 0.3% → 0.2%−204,343 shares
Holdings
As of Dec 31, 2022. Changes are in shares against Sep 30, 2022, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine, Inc.COM · shares New | 14.3% | $246.8M | — | ||||||||
| Verve Therapeutics Inc.COM · shares −3.9% · price −43.7% | 11.9% | $204.1M | −$158.2M | ||||||||
| UiPathCL A · shares 0% · price +0.8% | 10.4% | $178.8M | +$1.4M | ||||||||
| Dexcom IncCOM · shares −38% · price +40.6% | 8.2% | $141.6M | +$40.9M | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price −19.9% | 8.1% | $139.0M | −$34.5M | ||||||||
| Eqrx Inc.COM · shares +0.3% · price −50.3% | 6.8% | $117.3M | −$118.4M | ||||||||
| SnowflakeCL A · shares 0% · price −15.5% | 4.5% | $76.9M | −$14.2M | ||||||||
| CrowdStrikeCL A · shares New | 3.8% | $65.5M | — | ||||||||
| Freshworks IncCLASS A COM · shares 0% · price +13.4% | 3.4% | $59.4M | +$7.0M | ||||||||
| Oscar Health Inc.CL A · shares 0% · price −50.7% | 3.4% | $59.1M | −$60.8M | ||||||||
| Gitlab Inc.CLASS A COM · shares +118% · price −11.3% | 3.4% | $58.8M | −$3.4M | ||||||||
| Lyft IncCL A COM · shares −14% · price −16.3% | 3.4% | $57.9M | −$11.3M | ||||||||
| Duolingo Inc.CL A COM · shares 0% · price −25.3% | 2.9% | $50.1M | −$17.0M | ||||||||
| RobinhoodCOM CL A · shares 0% · price −19.4% | 2.3% | $40.1M | −$9.7M | ||||||||
| Benson Hill Inc.COMMON STOCK · shares 0% · price −5.7% | 2.3% | $39.7M | −$2.4M | ||||||||
| Relay Therapeutics Inc.COM · shares 0% · price −33.2% | 1.4% | $23.4M | −$11.7M | ||||||||
| Lyell Immunopharma Inc.COM · shares 0% · price −52.7% | 1.2% | $20.4M | −$22.6M | ||||||||
| Desktop Metal Inc.COM CL A · shares 0% · price −47.5% | 0.87% | $15.0M | −$13.6M | ||||||||
| 23andme Holding Co.CLASS A COM · shares 0% · price −24.5% | 0.85% | $14.6M | −$4.7M | ||||||||
| Beam Therapeutics Inc.COM · shares 0% · price −17.9% | 0.73% | $12.6M | −$2.7M | ||||||||
| Monte Rosa Therapeutics Inc.COM · shares 0% · price −6.9% | 0.65% | $11.1M | −$819,846 | ||||||||
| Sana Biotechnology Inc.COM · shares 0% · price −34.2% | 0.65% | $11.1M | −$5.8M | ||||||||
| Illumina Inc.COM · shares 0% · price +6.0% | 0.63% | $10.8M | +$609,634 | ||||||||
| Rapt Therapeutics Inc.COM · shares 0% · price −17.7% | 0.62% | $10.7M | −$2.3M | ||||||||
| Invivyd Inc.COM · shares 0% · price −52.1% | 0.49% | $8.5M | −$9.3M | ||||||||
| Total · 51 positions | 100% | $1.72B | −$475.4M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2022 to Q4 2022: 49 stocks held throughout, down $475.4M (−25.7%).
- Dexcom Inc+$40.9M+41%
- Freshworks Inc+$7.0M+13%
- UiPath+$1.4M+1%
- Illumina Inc.+$609,634+6%
- Exact Sciences Corp+$394,880+52%
- Lyell Immunopharma Inc.−$22.6M−53%
- Planet Labs Pbc−$34.5M−20%
- Oscar Health Inc.−$60.8M−51%
- Eqrx Inc.−$118.4M−50%
- Verve Therapeutics Inc.−$158.2M−44%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |